1. Home
  2. UTMD vs SGMT Comparison

UTMD vs SGMT Comparison

Compare UTMD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Utah Medical Products Inc.

UTMD

Utah Medical Products Inc.

HOLD

Current Price

$63.80

Market Cap

206.5M

Sector

Health Care

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.94

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTMD
SGMT
Founded
1978
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
206.5M
169.4M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
UTMD
SGMT
Price
$63.80
$6.94
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$26.13
AVG Volume (30 Days)
6.4K
2.7M
Earning Date
04-23-2026
05-14-2026
Dividend Yield
1.91%
N/A
EPS Growth
N/A
N/A
EPS
0.82
N/A
Revenue
$38,520,000.00
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$78.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$52.00
$3.15
52 Week High
$71.81
$11.41

Technical Indicators

Market Signals
Indicator
UTMD
SGMT
Relative Strength Index (RSI) 38.48 48.51
Support Level $60.23 $6.07
Resistance Level $64.21 $7.20
Average True Range (ATR) 1.42 0.62
MACD -0.36 -0.15
Stochastic Oscillator 16.39 1.32

Price Performance

Historical Comparison
UTMD
SGMT

About UTMD Utah Medical Products Inc.

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: